Ventus Therapeutics’ Post

AI is already affecting medicine, biotech, and more, but how will it completely disrupt the healthcare industry in the near future? In the latest episode, I discuss this very question with Naveen Jain, the Founder and CEO of Viome. Take a look: https://lnkd.in/gVPCBf4D

Pierre Socha, Amadeus Partner, puts the biotech public markets under the microscope in this European Life Sciences Review article🔬 Despite biotech IPO challenges, venture capital is fuelling innovation in AI and synthetic biology, with the latter poised to become a $30 billion industry by 2026. This surge is transforming healthcare delivery, making it more accessible outside conventional hospitals. We're proud to support these groundbreaking innovations, delivered by the pioneering founders we back 🤝 Read the article here⬇️ https://bit.ly/3z4HmRR #LifeSciences #HealthTech #VentureCapital

Pierre Socha, Amadeus Partner, puts the biotech public markets under the microscope in this European Life Sciences Review article🔬 Despite biotech IPO challenges, venture capital is fuelling innovation in AI and synthetic biology, with the latter poised to become a $30 billion industry by 2026. This surge is transforming healthcare delivery, making it more accessible outside conventional hospitals. We're proud to support these groundbreaking innovations, delivered by the pioneering founders we back 🤝 Read the article here⬇️ https://bit.ly/3z4HmRR #LifeSciences #HealthTech #VentureCapital

In any given moment, we have two options: to step forward into growth or step back into safety - Abraham Maslow As the #pharmaceutical industry is experiencing a revolution driven by artificial intelligence and massive computing power, this decision is more critical than ever.… If #AI simplifies work by analyzing, filtering, sorting, predicting and recognizing huge volumes of data, ELEM’s #virtualhumans, developed in Barcelona Supercomputing Center's MareNostrum and deployed in a supercomputing cloud, are revolutionizing therapeutics development and patient prognosis, enabling large-scale reliable in-silico #clinicaltrials.  To step forward into the future of healthcare with ELEM, contact us at contact@elem.bio and request a demo of our platform. The future is now! #medtech #Healthtech #EUeic

I'm excited to be on the Diagnostics Panel at RESI in Boston on September 25 to talk about the risks, challenges, and path forward for investment in diagnostics. The past couple of years have been brutal for investment in diagnostics, and while our space is starting to recover, there are clear lessons to take from 2020-2022. 1) Investing in tools and kits, and investing in diagnostics, are not the same. Different customers, different markets, different challenges, different path to revenue and returns. 2) Great science, cool technology, concordant clinical validations do not mean there is a diagnostic test that 1) physicians will use to change how they practice or 2) that payors will pay for. If no one uses it, and/or no one pays for it, there is not a product. 3) Experience matters. Teams with no experience bringing clinical diagnostics to the market will have trouble anticipating timelines and capital requirements. 4) Boards can really mess up diagnostic companies. It's great to have big names, distinguished scientists, and blue chip investors on your board, but if you don't have anyone who can give expert guidance from experience, chances of success are lower. Try to find someone that can give clinical and commercial guidance, especially. Come join us! #diagnostics #RESIBoston #precisionmedicine #innovation

🔍 Insights from Matthias Kromayer at BayOConnect in Munich! 🔍 This week, Matthias Kromayer held a presentation at BayOConnect by BioM Biotech Cluster Development GmbH. Under the theme "Reflections on AI from an Agnostic VC Investor," Matthias shared MIG Capital’s reflections on the potential impact of #AI within the #biopharma value chain. Key points included: 🚀 The Fight: Understanding the role of AI in revolutionizing clinical trials. 📊 Analysis: Breaking down AI’s potential in enhancing trial design, site selection, real-time monitoring, and patient experiences. 🔍 Conclusion: Assessing AI’s transformative power across the biopharma value chain, from early development to market approval. #BayOConnect2024 was fun – see you next year! 💡 Bayerisches Staatsministerium für Wirtschaft, Landesentwicklung und Energie | Roche Deutschland

Four months ago, I met with José Esteban del Corral Sánchez, CEO of KeyZell, to share our visions about the ongoing transformation in medicine. I had heard fantastic things about KeyZell, and that meeting confirmed them✔️. KeyZell is the company leading what we call precision medicine on a global scale. They are renowned for their focus on personalized cancer treatments. From that meeting, a connection emerged between both of us and our organizations. We believe that together 💡 we can share knowledge and experiences. We both utilize AI and share an obsession with seeking technology-based health solutions. When we began planning the launch of VivaWell five years ago, one of the fundamental pillars we defined was to establish partnerships with other tech-based startups. We did this a few months ago with Shen.AI, and now with KeyZell. At VivaWell, we believe that collaborative environments are crucial for transforming health. 👉 And that’s exactly what we are doing. Media coverage: https://yhoo.it/3YAWWPP #healthtech #healthcare #health #AI #Biotech #Innovation

From recent biotech financings to regulating AI in medtech, here’s what’s happening in life sciences.

From recent biotech financings to regulating AI in medtech, here’s what’s happening in life sciences.

The implementation of GenAI in life sciences comes with critical ethical considerations that we must address to ensure a future where technology and humanity advance hand in hand. From analyzing vast amounts of structured data to extracting meaningful insights, C5i is paving the way for more efficient and innovative solutions. We leverage GenAI to tackle a wide range of challenges, from accelerating drug discovery and improving patient diagnostics to optimizing clinical trials and personalizing treatment plans.   Discover how C5i is leveraging GenAI in life sciences and driving business impact with our latest article by Kamal Kasi, VP C5i. Read more: https://lnkd.in/dcyd-skn #C5iHumanAIImpact #TransformativeIntelligence #GenAI #Innovation #FutureTech #TrustworthyAI #BusinessImpact